Sabinsa was honored to receive Engredea’s Functional Ingredients Editors’ Choice Award recognizing the company’s patented Curcumin C3 Reduct for Best Science. The award was presented to Sabinsa CEO Jay Nair and Anurag Pande, PhD, Sabinsa’s vice president of scientific affairs, in Sabinsa’s booth at Expo West/Engredea trade show in Anaheim, Calif., on Saturday March 8, 2014.
“The foundation of innovation is functional ingredients and research demonstrating ingredient safety and efficacy. Sabinsa’s Curcumin C3 Reduct takes curcumin to a whole new level by removing the one major obstacle to curcumin’s wide-scale product integration, and that’s its beautiful, though technically troublesome, yellow color,” said Todd Runestad, editor-in-chief of Functional Ingredients. “By delineating the tetrahydrocurcuminoids, then creating a white powder, Sabinsa has demonstrated how good science and technical innovation will continue to be the driver for successful ingredient launches. We salute Sabinsa.”
“We express our gratitude to the excellent team of hard working and talented scientists who are tirelessly guided by Dr. Majeed, whose vision has been the hallmark of the success of the group,” said Mr. Nair.
As a color-free extract with superior solubility and pH stability than curcuminoids, Curcumin C3 Reduct provides more formulation options to manufacturers.
Curcumin C3 Reduct, Sabinsa’s patented and clinically safe 95% tetrahydrocurcuminoids is the result of the company’s research into metabolites of curcuminoids that have unraveled the role of tetrahydrocurcuminoids as not only the major metabolites but also pharmacologically superior than curcuminoids themselves. It is not the curcumin, but its metabolite, tetrahydrocurcumin (THC), which is responsible for its biological function in the body.
Curcumin C3 Reduct, tetrahydrocurcuminoids (THCs), the cascading antioxidants and the major metabolites of Curcuminoids, are the colorless hydrogenated compounds derived from Sabinsa’s Curcumin C3 Complex® curcuminoids: curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is the main phenolic compound. As a cascading antioxidant, in comparison to a standalone antioxidant, Curcumin C3 Reduct will act as an antioxidant for a longer time and show cumulatively stronger activity.
With higher bioavailability in the gut compared to parent curcuminoids, Curcumin C3 Reduct can be delivered in a smaller tablet or capsule. Sabinsa's recommended Curcumin C3 Complex dosage is 1500mg/daily, but new Curcumin C3 Reduct is recommended at 400 mg/daily.
Curcumin C3 Reduct is covered by these strictly enforced patents: US6653327, AU2006235807, EP1171144, EP1328263, NZ514884, US8119696, and JP2000-610495. It is Kosher and Halal certified, and allergen-free.